Zoetis Reports Clinical Data of Librela for Canine Osteoarthritis Pain
Shots:
- Zoetis has reported the self-sponsored UK trial data on Librela (bedinvetmab) to manage canine osteoarthritis (OA) pain
- Trial assessed Librela (n=52) vs meloxicam (n=49) over 8wks in newly or previously diagnosed OA dogs (N=101), who only received nutraceuticals, evaluating COI score changes as the 1EP; AE differences were inconclusive due to small sample size & short study duration
- Trial showed Librela & meloxicam managed OA pain from Day 14, with both improving over 56 days period. More dogs completed the study in Librela arm (44 vs 33), & while COI score reductions favored Librela, the difference was insignificant; data published in the Frontiers in Veterinary Science
Ref: Zoetis | Image: Zoetis
Related News:- Zoetis Collaborates with Danone to Develop Sustainable Practices in Dairy Farming Using Genetic Innovation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
